Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00001958 |
Recruitment Status :
Completed
First Posted : January 19, 2000
Last Update Posted : March 4, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This 12-month study will evaluate the safety and effectiveness of hydroxyurea in treating beta-thalassemia, a type of anemia caused by defective hemoglobin (the oxygen-carrying pigment in blood). Hemoglobin is composed of two protein chains-alpha globin chains and beta globin chains; patients with beta-thalassemia do not make beta globin. Patients often require frequent red blood cell transfusions. This leads to iron overload, which, in turn, requires iron chelation therapy (removal of iron from the blood).
Some drugs, including hydroxyurea, can stimulate production of a third type of protein chain called gamma chains. In the womb, the fetus makes this type of protein instead of beta globin. It is not until after birth, when the fetus no longer produces gamma globin that the beta globin deficiency becomes apparent. Gamma chain synthesis improves hemoglobin and red blood cell production, correcting the anemia. This study will determine if and at what dose hydroxyurea treatment reduces patients' need for red blood cell transfusions and whether certain factors might predict which patients are likely benefit from this treatment.
Patients 15 years and older with moderately severe beta-thalassemia may be eligible for this study. Participants will take hydroxyurea daily at a dose calculated according to the patient's body size. Blood will be drawn weekly to measure blood cell and platelet counts. The drug dosage may be increased after 12 weeks of treatment and again after 24 weeks if the white cell and platelet counts remain stable. Patients who respond dramatically to treatment may continue to receive hydroxyurea for up to 3 years.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Beta Thalassemia Hemoglobinopathy | Drug: Hydroxyurea | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 100 participants |
Primary Purpose: | Treatment |
Official Title: | Effect of Hydroxyurea on the Level of Ineffective Erythropoiesis, Transfusion Requirement, and Fetal Hemoglobin Synthesis in Patients With Beta-Thalassemia-Intermedia |
Study Start Date : | December 1999 |
Study Completion Date : | February 2002 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Beta-Thalassemia Intermedia patients.
Steady-state Hb values greater than 6.5gm/dl (unrelated to transfusion)
Males and females.
Patients greater than 15 years of age.
Patients who are transfusion-requiring but not dependent will be offered the opportunity to enroll.
Stable renal and hepatic function
Willingness to use appropriate birth control measures.
Ability to give informed consent.
No beta-thalassemia major.
No blood transfusion requirement greater than 1 unit every 2 months over the last 12 months.
No patients with WBC less than 4000/micrograms.
No one with a platelet count less than 150,000/micrograms.
No evidence of active viral infective, including viral hepatitis.
No abnormal liver function test (ALT or AST greater than 2.5 x normal).
No abnormal renal function test (creatinine greater 1.5 mg/dl).
No HIV positive blood test.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001958
United States, Maryland | |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | |
Bethesda, Maryland, United States, 20892 |
ClinicalTrials.gov Identifier: | NCT00001958 |
Other Study ID Numbers: |
000040 00-DK-0040 |
First Posted: | January 19, 2000 Key Record Dates |
Last Update Posted: | March 4, 2008 |
Last Verified: | February 2002 |
Gamma Gene Hemoglobin Switching Erythropoiesis |
HbE Hemoglobin Chain Synthesis Imbalance Cooley's Anemia Beta-Thalassemia Intermedia |
Thalassemia beta-Thalassemia Hemoglobinopathies Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases |
Genetic Diseases, Inborn Hydroxyurea Antineoplastic Agents Antisickling Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Nucleic Acid Synthesis Inhibitors |